Lys420

Site Information
GIEYkVGkFPFAANS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 461157
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 )
Disease tissue studied:	colorectal cancer ( 25 , 26 ) , colorectal carcinoma ( 25 , 26 ) , gastric cancer ( 14 ) , leukemia ( 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , chronic myelogenous leukemia ( 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , liver cancer ( 42 ) , hepatocellular carcinoma ( 42 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , non-small cell lung cancer ( 2 , 3 , 4 , 7 , 8 , 9 , 12 , 13 , 15 , 16 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 4 , 7 , 8 , 13 ) , non-small cell large cell lung carcinoma ( 2 , 8 ) , non-small cell squamous cell lung carcinoma ( 1 , 16 ) , small-cell lung cancer ( 5 , 6 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 7 ) , Cal-12T (pulmonary) ( 3 ) , Calu-3 (pulmonary) ( 9 ) , DMS153 (pulmonary) ( 4 ) , DMS53 (pulmonary) ( 6 ) , DMS79 (pulmonary) ( 5 ) , HCC15 (pulmonary) ( 1 ) , HCC44 (pulmonary) ( 3 ) , HCC78 (pulmonary) ( 2 ) , HCC827 (pulmonary) ( 9 ) , HCT116 (intestinal) ( 25 , 26 , 29 , 32 , 33 , 40 , 41 ) , HCT15 (intestinal) ( 39 ) , HeLa (cervical) ( 10 ) , HepG2 (hepatic) ( 42 ) , HT-29 (intestinal) ( 36 ) , Jurkat (T lymphocyte) ( 11 ) , K562 (erythroid) ( 18 , 19 , 20 , 21 , 22 , 23 , 24 , 31 ) , LOU-NH91 (squamous) ( 1 ) , lung ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , MKN-45 (gastric) ( 14 ) , NCI-H128 (pulmonary) ( 5 ) , NCI-H1299 (pulmonary) ( 8 ) , NCI-H1355 (pulmonary) ( 7 ) , NCI-H1417 (pulmonary) ( 5 ) , NCI-H1437 (pulmonary) ( 3 , 4 ) , NCI-H1650 (pulmonary) ( 9 ) , NCI-H1666 (pulmonary) ( 3 ) , NCI-H1703 (squamous) ( 1 , 16 ) , NCI-H1734 (pulmonary) ( 8 ) , NCI-H1781 (pulmonary) ( 2 ) , NCI-H1792 (pulmonary) ( 7 ) , NCI-H1944 (pulmonary) ( 8 ) , NCI-H1975 (pulmonary) ( 9 ) , NCI-H2073 (pulmonary) ( 1 , 4 ) , NCI-H209 (pulmonary) ( 4 , 5 ) , NCI-H2106 (pulmonary) ( 9 ) , NCI-H2228 (pulmonary) ( 2 , 13 ) , NCI-H23 (pulmonary) ( 7 ) , NCI-H2342 (pulmonary) ( 1 ) , NCI-H2405 (pulmonary) ( 3 ) , NCI-H3122 (pulmonary) ( 2 , 12 ) , NCI-H3255 (pulmonary) ( 15 ) , NCI-H358 (pulmonary) ( 8 ) , NCI-H441 (pulmonary) ( 7 ) , NCI-H446 (pulmonary) ( 6 ) , NCI-H460 (pulmonary) ( 8 ) , NCI-H524 (pulmonary) ( 5 ) , NCI-H526 (pulmonary) ( 6 ) , NCI-H661 (pulmonary) ( 2 ) , NCI-H69 (pulmonary) ( 6 ) , NCI-H716 (intestinal) ( 37 , 38 ) , NCI-H82 (pulmonary) ( 6 ) , NCI-H838 (pulmonary) ( 4 ) , SNU-C2B (intestinal) ( 34 , 35 ) , SW620 (intestinal) ( 30 )

References
1	Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
11	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
12	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
14	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
15	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
16	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
17	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
18	Moritz A (2010) CST Curation Set: 9922; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
19	Moritz A (2010) CST Curation Set: 9919; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
20	Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
21	Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
22	Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
23	Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
24	Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
25	Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
26	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
27	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
28	Li Y (2008) CST Curation Set: 4646; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989 Curated Info
29	Li Y (2006) CST Curation Set: 1999; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'\|\|' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
30	Li Y (2006) CST Curation Set: 1973; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
31	Moritz A (2006) CST Curation Set: 1968; Year: 2006; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
32	Li Y (2006) CST Curation Set: 1658; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
33	Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
34	Li Y (2006) CST Curation Set: 1640; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
35	Li Y (2006) CST Curation Set: 1641; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
36	Li Y (2006) CST Curation Set: 1632; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
37	Li Y (2006) CST Curation Set: 1566; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
38	Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
39	Li Y (2006) CST Curation Set: 1472; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
40	Li Y (2005) CST Curation Set: 966; Year: 2005; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
41	Li Y (2005) CST Curation Set: 967; Year: 2005; Biosample/Treatment: cell line, HCT116/EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
42	Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info